This study will test the safety of ipilimumab to see what effects, if any, the drug has when
used as maintenance therapy for people with relapsed/refractory multiple myeloma who have
received chemotherapy and allogeneic hematopoietic stem cell transplant (AHCT). The
investigators also want to find out whether giving ipilimumab after chemotherapy and AHCT is
a better way to control the multiple myeloma than chemotherapy and AHCT alone.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.